Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Cancer Chemother Pharmacol
    June 2018
  1. XU C, Ravva P, Dang JS, Laurent J, et al
    A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.
    Cancer Chemother Pharmacol. 2018 Jun 18. pii: 10.1007/s00280-018-3621.
    >> Share

  2. RODON J, Perez-Fidalgo A, Krop IE, Burris H, et al
    Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
    Cancer Chemother Pharmacol. 2018 Jun 7. pii: 10.1007/s00280-018-3610.
    >> Share

  3. IIZUMI S, Shimomura A, Shimoi T, Sudo K, et al
    Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study.
    Cancer Chemother Pharmacol. 2018 Jun 5. pii: 10.1007/s00280-018-3617.
    >> Share

    May 2018
  4. HUANG JF, Wen CJ, Zhao GZ, Dai Y, et al
    Overexpression of ABCB4 contributes to acquired doxorubicin resistance in breast cancer cells in vitro.
    Cancer Chemother Pharmacol. 2018 May 18. pii: 10.1007/s00280-018-3603.
    >> Share

  5. LEUNG HW, Ko CH, Yue GG, Herr I, et al
    The natural agent 4-vinylphenol targets metastasis and stemness features in breast cancer stem-like cells.
    Cancer Chemother Pharmacol. 2018 May 18. pii: 10.1007/s00280-018-3601.
    >> Share

  6. LITVIAKOV N, Tsyganov M, Larionova I, Ibragimova M, et al
    Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy.
    Cancer Chemother Pharmacol. 2018 May 4. pii: 10.1007/s00280-018-3594.
    >> Share

    March 2018
  7. KIMURA K, Iwamoto M, Tanaka S, Yamamoto D, et al
    A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
    Cancer Chemother Pharmacol. 2018 Mar 28. pii: 10.1007/s00280-018-3567.
    >> Share

    February 2018
  8. CITI V, Del Re M, Martelli A, Calderone V, et al
    Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
    Cancer Chemother Pharmacol. 2018 Feb 23. pii: 10.1007/s00280-018-3543.
    >> Share

  9. NAKAYAMA T, Sagara Y, Takashima T, Matsunami N, et al
    Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).
    Cancer Chemother Pharmacol. 2018 Feb 21. pii: 10.1007/s00280-018-3544.
    >> Share

  10. LIU Z, Tao Z, Zhang Q, Wan S, et al
    YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells.
    Cancer Chemother Pharmacol. 2018 Feb 1. pii: 10.1007/s00280-018-3535.
    >> Share

    December 2017
  11. ZHOU X, Qiao G, Wang X, Song Q, et al
    CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.
    Cancer Chemother Pharmacol. 2017 Dec 14. pii: 10.1007/s00280-017-3500.
    >> Share

  12. SHIEN T, Doihara H, Sato N, Anan K, et al
    Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.
    Cancer Chemother Pharmacol. 2017 Dec 1. pii: 10.1007/s00280-017-3491.
    >> Share

    October 2017
  13. LI C, Wang B, Chen SC, Wada R, et al
    Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
    Cancer Chemother Pharmacol. 2017 Oct 11. doi: 10.1007/s00280-017-3440.
    >> Share

    September 2017
  14. TAGAWA N, Sugiyama E, Tajima M, Sasaki Y, et al
    Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer.
    Cancer Chemother Pharmacol. 2017 Sep 1. doi: 10.1007/s00280-017-3425.
    >> Share

    August 2017
  15. HUANG S, Wang D, Zhang S, Huang X, et al
    Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
    Cancer Chemother Pharmacol. 2017 Aug 4. doi: 10.1007/s00280-017-3393.
    >> Share

  16. PARK WS, Park GJ, Han S, Ban S, et al
    Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients.
    Cancer Chemother Pharmacol. 2017;80:363-369.
    >> Share

    July 2017
  17. PANIS C, Binato R, Correa S, Victorino VJ, et al
    Short infusion of paclitaxel imbalances plasmatic lipid metabolism and correlates with cardiac markers of acute damage in patients with breast cancer.
    Cancer Chemother Pharmacol. 2017 Jul 8. doi: 10.1007/s00280-017-3384.
    >> Share

  18. PEER CJ, Lee JM, Roth J, Rodgers L, et al
    Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.
    Cancer Chemother Pharmacol. 2017;80:165-175.
    >> Share

  19. SMIYUN G, Azarenko O, Miller H, Rifkind A, et al
    betaIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
    Cancer Chemother Pharmacol. 2017;80:151-164.
    >> Share

    June 2017
  20. TSYGANOV MM, Freidin MB, Ibragimova MK, Deryusheva IV, et al
    Genetic variability in the regulation of the expression cluster of MDR genes in patients with breast cancer.
    Cancer Chemother Pharmacol. 2017 Jun 10. doi: 10.1007/s00280-017-3354.
    >> Share

  21. TANABE Y, Shimizu C, Hamada A, Hashimoto K, et al
    Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
    Cancer Chemother Pharmacol. 2017;79:1179-1186.
    >> Share

    May 2017
  22. XU YL, Yao R, Li J, Zhou YD, et al
    FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer.
    Cancer Chemother Pharmacol. 2017 May 10. doi: 10.1007/s00280-017-3319.
    >> Share

    April 2017
  23. MOUSAVI E, Tavakolfar S, Almasirad A, Kooshafar Z, et al
    In vitro and in vivo assessments of two novel hydrazide compounds against breast cancer as well as mammary tumor cells.
    Cancer Chemother Pharmacol. 2017 Apr 27. doi: 10.1007/s00280-017-3318.
    >> Share

  24. REN YQ, Wang HJ, Zhang YQ, Liu YB, et al
    WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206.
    Cancer Chemother Pharmacol. 2017 Apr 8. doi: 10.1007/s00280-017-3302.
    >> Share

    March 2017
  25. CHE J, Huang Y, Xu C, Zhang P, et al
    Increased ceramide production sensitizes breast cancer cell response to chemotherapy.
    Cancer Chemother Pharmacol. 2017 Mar 29. doi: 10.1007/s00280-017-3292.
    >> Share

  26. ROCCA A, Cecconetto L, Passardi A, Melegari E, et al
    Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.
    Cancer Chemother Pharmacol. 2017 Mar 24. doi: 10.1007/s00280-017-3279.
    >> Share

  27. TANDIA M, Mhiri A, Paule B, Saffroy R, et al
    Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
    Cancer Chemother Pharmacol. 2017 Mar 13. doi: 10.1007/s00280-017-3268.
    >> Share

    February 2017
  28. WANG Z, Chen J, Zhong MZ, Huang J, et al
    Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients.
    Cancer Chemother Pharmacol. 2017 Feb 27. doi: 10.1007/s00280-017-3248.
    >> Share

  29. KONG X
    Reply to: comment on "Meta-analysis of GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer".
    Cancer Chemother Pharmacol. 2017 Feb 22. doi: 10.1007/s00280-016-3230.
    >> Share

    January 2017
  30. QUARTINO AL, Li H, Jin JY, Wada DR, et al
    Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
    Cancer Chemother Pharmacol. 2017 Jan 10. doi: 10.1007/s00280-016-3218.
    >> Share

  31. ZHANG HY, Liang F, Zhang JW, Wang F, et al
    Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205.
    Cancer Chemother Pharmacol. 2017 Jan 6. doi: 10.1007/s00280-016-3208.
    >> Share

  32. CARGNIN S, Terrazzino S
    Comment to: GSTP1, GSTM1 and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis.
    Cancer Chemother Pharmacol. 2017 Jan 6. doi: 10.1007/s00280-016-3229.
    >> Share

  33. TAKAHASHI S, Kobayashi T, Tomomatsu J, Ito Y, et al
    LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer.
    Cancer Chemother Pharmacol. 2017;79:131-138.
    >> Share

  34. CHAN JC, Ong PS, Lim P, Teng PX, et al
    Synergistic disruption of ERalpha/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.
    Cancer Chemother Pharmacol. 2017;79:117-130.
    >> Share

    October 2016
  35. KONG X, Li Z, Li X
    GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis.
    Cancer Chemother Pharmacol. 2016.
    >> Share

    August 2016
  36. SONG JG, Lee YS, Park JA, Lee EH, et al
    Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein.
    Cancer Chemother Pharmacol. 2016.
    >> Share

  37. PARK JH, Kang MJ, Ahn JH, Kim JE, et al
    Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change afte
    Cancer Chemother Pharmacol. 2016.
    >> Share

    July 2016
  38. ZHANG X, Bai W
    Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.
    Cancer Chemother Pharmacol. 2016.
    >> Share

  39. LI C, Wang B, Lu D, Jin JY, et al
    Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.
    Cancer Chemother Pharmacol. 2016.
    >> Share

    June 2016
  40. YOSHITOMI S, Taira N, Doihara H, Mizoo T, et al
    A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.
    Cancer Chemother Pharmacol. 2016.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016